The First Information- and AI-Driven Gerotherapeutics Aimed at an Aging-Specific Target
Aging is the primary risk factor for chronic diseases, including cancer, Alzheimer’s Disease, diabetes, osteoarthritis, macular degeneration, along with many others. Gerotherapeutics aim to target aging’s underlying biological processes to extend healthspan and reduce healthcare burdens. It has been said that a successful gerotherapeutic would have a value that is too high to calculate — it instantly would become the most valuable medical intervention in history because of the number of person-years of healthy life that could be manufactured.
While traditional pharmaceuticals act by binding to specific receptors or regulatory molecules to alter biological functions, MitoXcel™ Technology introduces a revolutionary new class of peptide therapeutics whose effects are determined by the informational content of their amino acid sequences—much like DNA conveys genetic instructions through its nucleotide sequence. Instead of relying on a single, defined chemical entity, MitoXcel™ Technology is a powerful family of peptides—each precisely engineered to meet a unique set of design rules based on their amino acid sequences. Only those that match the MitoXcel™ blueprint qualify, ensuring consistent performance at the molecular level. Thus, MitoXcel™ peptides are the first ever information-based gerotherapeutics, specifically engineered to target the age-related decline in Mitochondrial Membrane Potential (Δψm) observed across all living organisms. By addressing this decline, MitoXcel™ reverses aging-related changes through two distinct mitochondrial-mediated mechanisms of action.
SENOTHERAPEUTIX is actively expanding a comprehensive database that links specific peptide sequences to preclinical outcomes related to aging reversal. Through an iterative learning process, MitoXcelAI™—the platform’s proprietary artificial intelligence engine—analyzes this growing dataset to train and refine predictive algorithms. This continuous feedback loop enhances the design rules that define MitoXcel™ Technology, much like the iPhone periodically updates its operating system, ensuring its evolution as a best-in-class, information-engineered solution for combating age-related decline.
In 2017, SENOTHERAPEUTIX, Inc. was founded in Houston, TX focused on developing gerotherapeutics to improve healthspan and increase lifespan. The Company’s dramatic discoveries and innovative technologies in the fields of geroscience and longevity medicine, have been spun out into four wholly owned subsidiaries of SENOTHERAPEUTIX, Inc.: (1) Eos SENOLYTIX, a longevity company developing novel MitoXcel™ geropeptides to improve healthspan and increase lifespan (2) Perseus SENOLYTIX, an oncology company developing novel MitoXcel™ peptides to target cancer via this same novel mechanism as a potentially safe and effective new class of cancer therapeutics (3) Phoenix SENOLYTIX, developing novel, controllable gene therapies utilizing our proprietary ApoptiCIDe™ purposeful cell elimination technology to directly target senescent cells to improve healthspan and increase lifespan and (4) Ponce Aurora, launching Yuuth™ – the first cosmetics for the digital age – powered by MitoXcel™ Technology.
Eos SENOLYTIX’s PTC-2105, PTC-2107, and PTC-2113, Perseus SENOLYTIX’s PTC-2110 and Ponce Aurora’s PTC-2111 and PTC-2116 are all powered by MitoXcel™ Technology
Eos SENOLYTIX™, Perseus SENOLYTIX™, Phoenix SENOLYTIX™ and Ponce Aurora™ are affiliated with SENOTHERAPEUTIX™, Inc. Visit our affiliate Companies to learn more about them!
